PaySign, the Technology sector company, was revisited by a Wall Street analyst today. Analyst Gary Prestopino from Barrington maintained a Buy rating on the stock and has a $8.50 price target.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Gary Prestopino has given his Buy rating due to a combination of factors including PaySign’s impressive financial performance and strategic growth initiatives. The company reported a significant increase in revenue by 33.1% to $19.1 million and a remarkable 101.8% rise in adjusted EBITDA to $4.51 million for Q2/25, surpassing both internal and consensus expectations. This growth was driven by the robust performance of the Pharma Patient Affordability segment, which saw a 190% increase in revenue, highlighting the company’s ability to capitalize on high-growth opportunities.
Furthermore, PaySign’s strategic expansion, including the addition of 123 new plasma donation centers and seven new Pharma Patient Affordability programs, positions it well for future growth. The company’s proprietary dynamic business rules technology enhances its competitive edge by effectively addressing market challenges, thereby attracting new clients and expanding existing programs. These factors, combined with an improved gross profit margin and a strong pipeline for further growth, underpin Prestopino’s positive outlook on PaySign’s stock.
According to TipRanks, Prestopino is a 5-star analyst with an average return of 10.0% and a 52.34% success rate. Prestopino covers the Consumer Cyclical sector, focusing on stocks such as OPENLANE, Liquidity Services, and Commercial Vehicle Group.
In another report released on August 7, D.A. Davidson also maintained a Buy rating on the stock with a $9.00 price target.